Gene panel testing using the OncoGuideTM National Cancer Center (NCC) Oncopanel System (National Cancer Center, Tokyo, Japan, and Sysmex Corporation, Kobe, Japan) revealed two pathogenic somatic mutations of SMARCA4 in the tumor (c.2866_2867delC>T [p.L956fs*2] and c.3543delC [p.Q1182fs*34]). The gene discussed is SMARCA4; the disease is neoplasm.